Home Stock

Stock Research: Bionano Genomics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Bionano Genomics

NAQ:BNGO US09075F1075
23
  • Value
    95
  • Growth
    1
  • Safety
    Safety
    42
  • Combined
    40
  • Sentiment
    37
  • 360° View
    360° View
    23
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Bionano Genomics, Inc. provides genome analysis solutions for researchers and clinicians, offering optical genome mapping (OGM) and platform-agnostic software for analyzing genomic variations, as well as nucleic acid extraction and purification solutions. In the last fiscal year, the company had a market cap of $11 million, profits of $0 million, revenue of $31 million, and 98 employees.

more

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Bionano Genomics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Bionano Genomics. Only the consolidated Value Rank has an attractive rank of 95, which means that the share price of Bionano Genomics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 95% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 1, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 42, meaning the company has a riskier financing structure than 58% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 63% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 37. ...read more

more
Strongest Rank Growth
Weakest Rank Refinancing
Country USA
Industry Life Sciences Tools & Services
Size Small
Website bionano.com
Index
Bionano Genomics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
95 47 83 37
Growth
1 15 53 69
Safety
Safety
42 89 78 72
Sentiment
37 4 32 69
360° View
360° View
23 10 84 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 3 91 100
Opinions Change
50 50 50 50
Pro Holdings
n/a 18 41 50
Market Pulse
98 5 5 30
Sentiment
37 4 32 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
95 47 83 37
Growth
1 15 53 69
Safety Safety
42 89 78 72
Combined
40 44 95 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
93 93 86 1
Price vs. Earnings (P/E)
53 18 18 18
Price vs. Book (P/B)
93 14 91 87
Dividend Yield
1 1 1 1
Value
95 47 83 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
8 6 96 97
Profit Growth
32 88 10 17
Capital Growth
17 37 87 97
Stock Returns
5 5 3 9
Growth
1 15 53 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
52 70 74 45
Refinancing
99 92 89 91
Liquidity
17 16 9 14
Safety Safety
42 89 78 72

Similar Stocks

Discover high‑ranked alternatives to Bionano Genomics and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews